Molecular Heterogeneity, Biomarker Discovery, and Targeted Therapy in Asthma - Genomic Biomarkers for Pharmaceutical Development - page 91

[64] Nair P, Pizzichini MM, Kjarsgaard M, Inman MD, Efthimiadis A, Pizzichini E, et al. Mepolizumab for pred-
nisone-dependent asthma with sputum eosinophilia. N Engl J Med 2009;360:985-93.
[65] Miller MK, Lee JH, Miller DP, Wenzel SE. Recent asthma exacerbations: a key predictor of future exacerba-
tions. Respir Med 2007;101:481-9.
[66] Castro M, Mathur S, Hargreave F, Boulet LP, Xie F, Young J, et al. Reslizumab for poorly controlled, eosino-
philic asthma: a randomized, placebo-controlled study. Am J Respir Crit Care Med 2011.
[67] Molino NA, Novak R, Silverman RA, Rowe BH, Smithline H, Khan F, et al. Reduction in the number and
severity of exacerbations following acute severe asthma: results of a placebo-controlled, randomized clinical
trial with benralizumab. Am J Respir Crit Care Med 2012;185:A2753.
[68] Pavord ID, Korn S, Howarth P, Bleecker ER, Buhl R, Keene ON, et al. Mepolizumab for severe eosinophilic
asthma (DREAM): a multicenter, double-blind, placebo-controlled trial. Lancet 2012;380:651-9.
[69] Otulana BA, Wenzel SE, Ind PW, Bowden A, Puthukkeril S, Tomkinson A, et al. A Phase IIb study of inhaled
pitrakinra, an IL-4/IL-13 antagonist, successfully identiied responder subpopulations of patients with uncon-
trolled asthma. Am J Respir Crit Care Med 2011;183:A6179.
[70] Corren J, Busse W, Meltzer EO, Mansield L, Bensch G, Fahrenholz J, et al. A randomized, controlled,
Phase II study of AMG 317, an IL-4Ralpha antagonist, in patients with asthma. Am J Respir Crit Care Med
2010;181:788-96.
[71] Piper E, Brightling C, Niven R, Oh C, Faggioni R, Poon K, et al. A Phase II placebo-controlled study of traloki-
numab in moderate-to-severe asthma. Eur Respir J 2013;41(2):330-8.
[72] Corren J, Lemanske RF, Hanania NA, Korenblat PE, Parsey MV, Arron JR, et al. Lebrikizumab treatment in
adults with asthma. N Engl J Med 2011;365:1088-98.
[73] Slager RE, Otulana BA, Hawkins GA, Yen YP, Peters SP, Wenzel SE, et al. IL-4 receptor polymorphisms predict
reduction in asthma exacerbations during response to an anti-IL-4 receptor alpha antagonist. J Allergy Clin
Immunol 2012;130(2):516-22.
[74] Woodruff PG, Modrek B, Choy DF, Jia G, Abbas AR, Ellwanger A, et al. T-helper type 2-driven inlammation
deines major subphenotypes of asthma. Am J Respir Crit Care Med 2009;180:388-95.
[75] Arron JR, Corren J, Matthews JG. Author response to correspondence on 'Lebrikizumab treatment in adults
with asthma'. N Engl J Med 2011;365:2433-4.
[76] McClintock D, Corren J, Hanania NA, Mosesova S, Lal P, Arron JR, et al. Lebrikizumab, an anti-IL-13 mono-
clonal antibody, reduces severe asthma exacerbations over 32 weeks in adults with inadequately controlled
asthma. Am J Respir Crit Care Med 2012;185:A3959.
[77] Scheerens H, Arron JR, Choy DF, Mosesova S, Lal P, Matthews JG. Lebrikizumab treatment reduces serum
periostin levels in asthma patients with elevated baseline levels of periostin. Am J Respir Crit Care Med
2012;185:A3960.
[78] FDA. Draft guidance for industry, clinical laboratories, and fda staff - in vitro diagnostic multivariate index
assays. 2007. http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/
ucm079148.htm .
[79] Carlson B. HER2 Tests: How Do We Choose? Biotechnol Healthcare 2008;5:23-7.